Holen Sie sich die Stockscreener-App
69.90
0.63%
-0.4338
Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten
Is Corcept Therapeutics Incorporated a good ESG investmentJuly 2025 Intraday Action & High Return Trade Guides - classian.co.kr
With 70% Institutional Ownership, Corcept Therapeutics Incorporated (NASDAQ:CORT) Is a Favorite Amongst the Big Guns - 富途牛牛
What Technical Tools Say About Corcept Therapeutics Incorporated Recovery2025 Trading Volume Trends & Safe Capital Growth Stock Tips - metal.it
Corcept Therapeutics Advances Liver Fat Reduction Study with Miricorilant - MSN
Corcept Therapeutics: Buy Rating Backed by Promising Developments in Glucocorticoid Modulation and Oncology Expansion - TipRanks
Watch for Bullish Crossover in Corcept Therapeutics IncorporatedJuly 2025 Closing Moves & Consistent Profit Focused Trading Strategies - beatles.ru
CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook - Yahoo Finance
5 Must-Read Analyst Questions From Corcept’s Q2 Earnings Call - Yahoo Finance
Corcept Therapeutics Insider Sold Shares Worth $2,512,452, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics director Swisher sells $159k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics officer sells $2.5M in shares By Investing.com - Investing.com Australia
Corcept therapeutics director Swisher sells $159k in shares - Investing.com
Corcept therapeutics officer sells $2.5M in shares - Investing.com
Corcept Therapeutics Announces CDO William Guyer's Share Buy and Sell Transactions - AInvest
Corcept Therapeutics: Pioneering a $2.8B Market in Type 2 Diabetes via Hypercortisolism Treatment - AInvest
Corcept's Q2 Demand Grows 60% Penetrating Large Type 2 Diabetes Market Early (NASDAQ:CORT) - Seeking Alpha
Corcept Therapeutics’ MOMENTUM Study: Assessing Hypercortisolism in Resistant Hypertension - TipRanks
Corcept Therapeutics Advances in Ovarian Cancer Treatment with New Phase 2 Study - TipRanks
Why Corcept Therapeutics' (NASDAQ:CORT) Earnings Are Better Than They Seem - Yahoo Finance
Assessing the Impact of Pre-Scheduled Insider Sales at Corcept Therapeutics on Investor Confidence and Market Dynamics - AInvest
Corcept Therapeutics Insider Sold Shares Worth $2,373,237, According to a Recent SEC Filing - MarketScreener
Corcept Therapeutics Insider Sold Shares Worth $393,128, According to a Recent SEC Filing - MarketScreener
Corcept therapeutics officer Lyon sells $393k in shares By Investing.com - Investing.com Nigeria
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock By Investing.com - Investing.com India
Corcept therapeutics (CORT) CEO Belanoff sells $2.74 million in stock - Investing.com
Cushings Syndrome Market Exclusive Report with Detailed Study - openPR.com
How does Corcept Therapeutics Incorporated compare to its industry peersLightning-fast growth - Jammu Links News
How strong is Corcept Therapeutics Incorporated company’s balance sheetTriple-digit wealth increases - Jammu Links News
How volatile is Corcept Therapeutics Incorporated stock compared to the marketGet professional advice for market timing - Jammu Links News
Corcept Therapeutics Analyst Rating Update: Canaccord Genuity Maintains 'Buy' Rating with Lowered Price Target to 137.00 USD - AInvest
What catalysts could drive Corcept Therapeutics Incorporated stock higher in 2025Dynamic profit opportunities - Jammu Links News
Why is Corcept Therapeutics Incorporated stock attracting strong analyst attentionFastest return on investment - Jammu Links News
What are the latest earnings results for Corcept Therapeutics IncorporatedInvest smarter with daily stock recommendations - Jammu Links News
What analysts say about Corcept Therapeutics Incorporated stockRealize exceptional returns through smart trading - Jammu Links News
CORT's Q2 Earnings Beat and Pipeline Momentum: A Case for Revisiting the Downside as a Buy Opportunity - AInvest
When is Corcept Therapeutics Incorporated stock expected to show significant growthTremendous financial leverage - Jammu Links News
Corcept Therapeutics (CORT): A High-Conviction Buy Amidst Breakthroughs in Cortisol-Modulating Therapies - AInvest
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q2 2025 Earnings Call Transcript - Insider Monkey
Corcept Therapeutics Second Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Published on: 2025-08-02 05:25:16 - metal.it
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates - MSN
Corcept Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Corcept Therapeutics Incorporated Recovery Hinges on Volume BreakoutNews Based Entry Opportunity Alerts Detected - metal.it
Corcept Faces Growing Pains As Earnings Miss The Mark - Finimize
Corcept Therapeutics Reports Q2 2025 Financial Results - The Globe and Mail
CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down - Yahoo Finance
A Quick Look at Today's Ratings for Corcept Therapeutics(CORT.US), With a Forecast Between $121 to $145 - 富途牛牛
Corcept Therapeutics 2025 Q2 Earnings Misses Targets as Net Income Declines 1% - AInvest
Corcept Therapeutics Q2 CY2025: Revenue Misses, Earnings BeatNews and Statistics - IndexBox
Corcept Therapeutics shares fall 3.38% premarket after Q2 revenue misses estimates. - AInvest
Corcept: Q2 Earnings Snapshot - Connecticut Post
Earnings call transcript: Corcept Therapeutics Q2 2025 earnings beat expectations By Investing.com - Investing.com Canada
0.12%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):